Skip to main content

Navigation group

Type at least 3 characters
2,747 articles

Articles

Original Research

Published on 29 Aug 2024

MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses

in Vaccines and Molecular Therapeutics

  • Patricia Pérez
  • David Astorgano
  • Guillermo Albericio
  • Sara Flores
  • Cristina Sánchez-Corzo
  • María A. Noriega
  • Pedro J. Sánchez-Cordón
  • Nuria Labiod
  • Rafael Delgado
  • José M. Casasnovas
MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses
Frontiers in Immunology
doi 10.3389/fimmu.2024.1420304
  • 1,113 views

Original Research

Published on 20 Aug 2024

Immunogenicity and safety of different combinations involving a third booster dose of SARS-CoV-2 inactivated vaccine, inactivated quadrivalent influenza vaccine, and 23-valent pneumococcal polysaccharide vaccine in adults aged ≥60 years: a phase 4, randomized, open-label study

in Vaccines and Molecular Therapeutics

  • Shuang Bai
  • Shanshan Zhou
  • Junnan Zhang
  • Weixin Chen
  • Min Lv
  • Jian Wang
  • Ao Zhang
  • Jiang Wu
  • Wei Zhao
Immunogenicity and safety of different combinations involving a third booster dose of SARS-CoV-2 inactivated vaccine, inactivated quadrivalent influenza vaccine, and 23-valent pneumococcal polysaccharide vaccine in adults aged ≥60 years: a phase 4, randomized, open-label study
Frontiers in Immunology
doi 10.3389/fimmu.2024.1437267
  • 1,023 views